Loading...
 
Register Log In Login with facebook

Blood pressure reduced by monthly 100,000 IU of vitamin D in those who were deficient – RCT Oct 2017

Effect of Monthly, High‐Dose, Long‐Term Vitamin D Supplementation on Central Blood Pressure Parameters: A Randomized Controlled Trial Substudy

Journal of the American Heart Association. 2017;6:e006802. published October 24, 2017, https://doi.org/10.1161/JAHA.117.006802John D. Sluyter, Carlos A. Camargo, Alistair W. Stewart, Debbie Waayer, Carlene M. M. Lawes, Les Toop, Kay‐Tee Khaw, Simon A. McG. Thom, Bernhard Hametner, Siegfried Wassertheurer, Kim H. Parker, Alun D. Hughes, Robert Scragg

VitaminDWiki

Hypertension Intervention trials using Vitamin D (any time period)

Similar: 50,000 IU twice a month prevented or treated the following

Diabetes + Heart Failure + Chronic Pain + Depression + Autism + Breast Cancer + Colon Cancer + Prostate Cancer + Preeclampsia + Premature Birth + Falls + Cognitive Decline + Respiratory Tract Infection + Influenza + Tuberculosis + Chronic Obstructive Pulmonary Disease + Lupus + Inflammatory Bowel Syndrome + Urinary Tract Infection (19 problems)


 Download the PDF from VitaminDWiki

Background The effects of monthly, high‐dose, long‐term (≥1‐year) vitamin D supplementation on central blood pressure (BP) parameters are unknown.

Methods and Results A total of 517 adults (58% male, aged 50–84 years) were recruited into a double‐blinded, placebo‐controlled trial substudy and randomized to receive, for 1.1 years (median; range: 0.9–1.5 years), either (1) vitamin D3 200 000 IU (initial dose) followed 1 month later by monthly 100 000‐IU doses (n=256) or (2) placebo monthly (n=261). At baseline (n=517) and follow‐up (n=380), suprasystolic oscillometry was undertaken, yielding aortic BP waveforms and hemodynamic parameters. Mean deseasonalized 25‐hydroxyvitamin D increased from 66 nmol/L (SD: 24) at baseline to 122 nmol/L (SD: 42) at follow‐up in the vitamin D group, with no change in the placebo group. Despite small, nonsignificant changes in hemodynamic parameters in the total sample (primary outcome), we observed consistently favorable changes among the 150 participants with vitamin D deficiency (<50 nmol/L) at baseline.

In this subgroup, mean changes in the vitamin D group (n=71) versus placebo group (n=79) were

  • −5.3 mm Hg (95% confidence interval CI, −11.8 to 1.3) for brachial systolic BP (P=0.11),
  • −2.8 mm Hg (95% CI, −6.2 to 0.7) for brachial diastolic BP (P=0.12),
  • −7.5 mm Hg (95% CI, −14.4 to −0.6) for aortic systolic BP (P=0.03),
  • −5.7 mm Hg (95% CI, −10.8 to −0.6) for augmentation index (P=0.03),
  • −0.3 m/s (95% CI, −0.6 to −0.1) for pulse wave velocity (P=0.02),
  • −8.6 mm Hg (95% CI, −15.4 to −1.9) for peak reservoir pressure (P=0.01), and
  • −3.6 mm Hg (95% CI, −6.3 to −0.8) for backward pressure amplitude (P=0.01).


Conclusions Monthly, high‐dose, 1‐year vitamin D supplementation lowered central BP parameters among adults with vitamin D deficiency but not in the total sample.

Clinical Trial Registration URL: http://www.anzctr.org.au. Unique identifier: ACTRN12611000402943.

Created by admin. Last Modification: Friday November 10, 2017 03:49:20 UTC by admin. (Version 6)

Attached files

ID Name Comment Uploaded Size Downloads
8686 Monthly blood pressure reduction.pdf admin 10 Nov, 2017 03:47 1.16 Mb 0
See any problem with this page? Report it to the webmaster.